LITHIUM CARBONATE tablet extended release

Pays: États-Unis

Langue: anglais

Source: NLM (National Library of Medicine)

Ingrédients actifs:

Lithium Carbonate (UNII: 2BMD2GNA4V) (Lithium cation - UNII:8H8Z5UER66)

Disponible depuis:

Cardinal Health

DCI (Dénomination commune internationale):

Lithium Carbonate

Composition:

Lithium Carbonate 450 mg

Type d'ordonnance:

PRESCRIPTION DRUG

Statut de autorisation:

Abbreviated New Drug Application

Résumé des caractéristiques du produit

LITHIUM CARBONATE- LITHIUM CARBONATE TABLET, EXTENDED RELEASE
CARDINAL HEALTH
----------
LITHIUM CARBONATE
EXTENDED-RELEASE TABLETS, USP
REV. 04/07
RX ONLY
WARNING
Lithium toxicity is closely related to serum lithium levels, and can
occur at doses close to
therapeutic levels. Facilities for prompt and accurate serum lithium
determinations should be
available before initiating therapy (see DOSAGE AND ADMINISTRATION).
DESCRIPTION
Lithium Carbonate is a white, light alkaline powder with molecular
formula Li
CO and molecular
weight 73.89. Lithium is an element of the alkali-metal group with
atomic number 3, atomic weight 6.94
and an emission line at 671 nm on the flame photometer.
Each extended-release tablet for oral administration contains 450 mg
of lithium carbonate. In addition,
each tablet contains the following inactive ingredients: Alginic Acid,
Corn Starch, Magnesium Stearate,
Povidone, and Yellow Iron Oxide. Lithium Carbonate Extended-Release
Tablets 450 mg are designed
to release a portion of the dose initially and the remainder
gradually; the release pattern of the extended
release tablets reduces the variability in lithium blood levels seen
with the immediate release dosage
forms.
This product meets USP Drug Release Test 2.
CLINICAL PHARMACOLOGY
Preclinical studies have shown that lithium alters sodium transport in
nerve and muscle cells and effects
a shift toward intraneuronal metabolism of catecholamines, but the
specific biochemical mechanism of
lithium action in mania is unknown.
INDICATIONS AND USAGE
Lithium carbonate is indicated in the treatment of manic episodes of
manic-depressive illness.
Maintenance therapy prevents or diminishes the intensity of subsequent
episodes in those manic-
depressive patients with a history of mania.
Typical symptoms of mania include pressure of speech, motor
hyperactivity, reduced need for sleep,
flight of ideas, grandiosity, elation, poor judgment, aggressiveness
and possibly hostility. When given
to a patient experiencing a manic episode, _lithium carbonate_ may
pro